201 related articles for article (PubMed ID: 38045035)
1. Ceragenins exhibit bactericidal properties that are independent of the ionic strength in the environment mimicking cystic fibrosis sputum.
Skłodowski K; Suprewicz Ł; Chmielewska-Deptuła SJ; Kaliniak S; Okła S; Zakrzewska M; Minarowski Ł; Mróz R; Daniluk T; Savage PB; Fiedoruk K; Bucki R
Front Microbiol; 2023; 14():1290952. PubMed ID: 38045035
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of CSA-131 and CSA-131 poloxamer form for the treatment of Stenotrophomonas maltophilia infections in cystic fibrosis.
Oyardi Ö; Savage PB; Erturan Z; Bozkurt-Guzel C
J Antimicrob Chemother; 2021 Jan; 76(2):443-450. PubMed ID: 33094334
[TBL] [Abstract][Full Text] [Related]
3. Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.
Durnaś B; Wnorowska U; Pogoda K; Deptuła P; Wątek M; Piktel E; Głuszek S; Gu X; Savage PB; Niemirowicz K; Bucki R
PLoS One; 2016; 11(6):e0157242. PubMed ID: 27315208
[TBL] [Abstract][Full Text] [Related]
4. Ceragenin-mediated disruption of Pseudomonas aeruginosa biofilms.
Wnorowska U; Łysik D; Piktel E; Zakrzewska M; Okła S; Lesiak A; Spałek J; Mystkowska J; Savage PB; Janmey P; Fiedoruk K; Bucki R
PLoS One; 2024; 19(2):e0298112. PubMed ID: 38346040
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro antimicrobial activities of CSA-142 and CSA-192, second-generation ceragenins, with CSA-13 against various microorganisms.
Bozkurt Guzel C; Oyardi O; B Savage P
J Chemother; 2018; 30(6-8):332-337. PubMed ID: 30663553
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial ceragenins inhibit biofilms and affect mammalian cell viability and migration
Olekson MA; You T; Savage PB; Leung KP
FEBS Open Bio; 2017 Jul; 7(7):953-967. PubMed ID: 28680809
[TBL] [Abstract][Full Text] [Related]
7. Effects of Ceragenins and Antimicrobial Peptides on the A549 Cell Line and an In Vitro Co-Culture Model of A549 Cells and
Oyardi O; Savage PB; Guzel CB
Pathogens; 2022 Sep; 11(9):. PubMed ID: 36145476
[No Abstract] [Full Text] [Related]
8. In vitro activities of antimicrobial peptides and ceragenins against Legionella pneumophila.
Birteksoz-Tan AS; Zeybek Z; Hacioglu M; Savage PB; Bozkurt-Guzel C
J Antibiot (Tokyo); 2019 May; 72(5):291-297. PubMed ID: 30755738
[TBL] [Abstract][Full Text] [Related]
9. Proteomic Analysis of Resistance of Gram-Negative Bacteria to Chlorhexidine and Impacts on Susceptibility to Colistin, Antimicrobial Peptides, and Ceragenins.
Hashemi MM; Holden BS; Coburn J; Taylor MF; Weber S; Hilton B; Zaugg AL; McEwan C; Carson R; Andersen JL; Price JC; Deng S; Savage PB
Front Microbiol; 2019; 10():210. PubMed ID: 30833936
[TBL] [Abstract][Full Text] [Related]
10. Antibiofilm activities of ceragenins and antimicrobial peptides against fungal-bacterial mono and multispecies biofilms.
Hacioglu M; Oyardi O; Bozkurt-Guzel C; Savage PB
J Antibiot (Tokyo); 2020 Jul; 73(7):455-462. PubMed ID: 32203127
[TBL] [Abstract][Full Text] [Related]
11. Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.
Payne JE; Dubois AV; Ingram RJ; Weldon S; Taggart CC; Elborn JS; Tunney MM
Int J Antimicrob Agents; 2017 Sep; 50(3):427-435. PubMed ID: 28666755
[TBL] [Abstract][Full Text] [Related]
12. Core-shell magnetic nanoparticles display synergistic antibacterial effects against
Niemirowicz K; Piktel E; Wilczewska AZ; Markiewicz KH; Durnaś B; Wątek M; Puszkarz I; Wróblewska M; Niklińska W; Savage PB; Bucki R
Int J Nanomedicine; 2016; 11():5443-5455. PubMed ID: 27799768
[TBL] [Abstract][Full Text] [Related]
13. Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo.
Durnaś B; Piktel E; Wątek M; Wollny T; Góźdź S; Smok-Kalwat J; Niemirowicz K; Savage PB; Bucki R
BMC Microbiol; 2017 Jul; 17(1):167. PubMed ID: 28747178
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.
Wnorowska U; Niemirowicz K; Myint M; Diamond SL; Wróblewska M; Savage PB; Janmey PA; Bucki R
Antimicrob Agents Chemother; 2015 Jul; 59(7):3808-15. PubMed ID: 25870055
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal and Fungicidal Activity of
Gruber M; Moser I; Nagl M; Lackner M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223376
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility and genotyping of microorganisms isolated from sputum culture of children with cystic fibrosis in an Iranian referral children's hospital.
Mamishi S; Akhlaghi A; Pourakbari B; Modaresi M; Haghi Ashtiani MT; Hosseinpour Sadeghi R; Shirzadi R; Shalchi Z; Mahmoudi S
Wien Med Wochenschr; 2023 May; 173(7-8):182-187. PubMed ID: 36167900
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Multidrug-Resistant Bacteria, Isolated from Water and Plants in Nigeria, to Ceragenins.
Hashemi MM; Mmuoegbulam AO; Holden BS; Coburn J; Wilson J; Taylor MF; Reiley J; Baradaran D; Stenquist T; Deng S; Savage PB
Int J Environ Res Public Health; 2018 Dec; 15(12):. PubMed ID: 30563216
[TBL] [Abstract][Full Text] [Related]
18. The Semi-Synthetic Peptide Lin-SB056-1 in Combination with EDTA Exerts Strong Antimicrobial and Antibiofilm Activity against Pseudomonas aeruginosa in Conditions Mimicking Cystic Fibrosis Sputum.
Maisetta G; Grassi L; Esin S; Serra I; Scorciapino MA; Rinaldi AC; Batoni G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28926942
[No Abstract] [Full Text] [Related]
19. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.
Sajjan US; Tran LT; Sole N; Rovaldi C; Akiyama A; Friden PM; Forstner JF; Rothstein DM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3437-44. PubMed ID: 11709321
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Activity of Ceragenins against Vancomycin-Susceptible and -Resistant
Hacioglu M; Yilmaz FN; Oyardi O; Bozkurt Guzel C; Inan N; Savage PB; Dosler S
Pharmaceuticals (Basel); 2023 Nov; 16(12):. PubMed ID: 38139770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
